Cerus Co. (NASDAQ:CERS) COO Sells $43,478.25 in Stock

Cerus Co. (NASDAQ:CERS) COO Vivek K. Jayaraman sold 29,985 shares of Cerus stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $1.45, for a total transaction of $43,478.25. Following the sale, the chief operating officer now directly owns 1,477,330 shares of the company’s stock, valued at $2,142,128.50. The trade was a 1.99 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Cerus Stock Performance

NASDAQ CERS remained flat at $1.45 during trading on Monday. 1,979,196 shares of the company’s stock were exchanged, compared to its average volume of 1,302,541. The company has a debt-to-equity ratio of 1.19, a current ratio of 2.59 and a quick ratio of 1.92. The stock has a market cap of $269.40 million, a price-to-earnings ratio of -13.18 and a beta of 1.56. Cerus Co. has a 52-week low of $1.38 and a 52-week high of $2.54. The company has a 50 day moving average of $1.72 and a 200 day moving average of $1.76.

Cerus (NASDAQ:CERS) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.01). The firm had revenue of $50.81 million during the quarter, compared to the consensus estimate of $50.81 million. Cerus had a negative net margin of 11.60% and a negative return on equity of 40.55%. On average, equities analysts forecast that Cerus Co. will post -0.08 EPS for the current fiscal year.

Institutional Trading of Cerus

A number of institutional investors have recently bought and sold shares of the business. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Cerus during the 4th quarter worth approximately $25,000. Squarepoint Ops LLC lifted its holdings in shares of Cerus by 2,084.7% during the 4th quarter. Squarepoint Ops LLC now owns 492,732 shares of the biotechnology company’s stock worth $759,000 after acquiring an additional 470,178 shares during the period. Two Sigma Advisers LP lifted its holdings in shares of Cerus by 249.5% during the 4th quarter. Two Sigma Advisers LP now owns 254,100 shares of the biotechnology company’s stock worth $391,000 after acquiring an additional 181,400 shares during the period. Two Sigma Investments LP lifted its holdings in shares of Cerus by 121.6% during the 4th quarter. Two Sigma Investments LP now owns 595,234 shares of the biotechnology company’s stock worth $917,000 after acquiring an additional 326,605 shares during the period. Finally, State of Wyoming lifted its holdings in shares of Cerus by 39.1% during the 4th quarter. State of Wyoming now owns 129,840 shares of the biotechnology company’s stock worth $200,000 after acquiring an additional 36,488 shares during the period. Institutional investors own 78.37% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $4.00 target price on shares of Cerus in a report on Friday, February 21st.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.